GlassScriptPhysician profile
Maimoona Nizami
NPI 1487971495
$1,064.28
in general payments reported to CMS, 2019-2025
32 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $114 · 2021: $32.14 · 2022: $175 · 2023: $269 · 2024: $186 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $596.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $80.75 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $79.89 | 2022-2023 | |
| Allergan, INC. | $59.14 | 2019-2020 | |
| Abbott Laboratories | $58.36 | 2023 | Proclaim, Freestyle Libre 3, Eterna |
| Sunovion Pharmaceuticals INC. | $57.78 | 2019 | |
| Janssen Pharmaceuticals, INC | $49.84 | 2021-2024 | Xarelto |
| Pfizer INC. | $48.88 | 2021-2023 | |
| Abiomed | $44.80 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $44.12 | 2024-2025 | Airsupra |
| Otsuka America Pharmaceutical, INC. | $40.92 | 2023-2025 | Rexulti, Nuedexta |
| Smith+Nephew, INC. | $34.85 | 2024 | Collagenase Santyl |
| Aquestive Therapeutics, INC. | $33.24 | 2022 | |
| Acadia Pharmaceuticals INC | $32.97 | 2019-2020 | |
| Novo Nordisk INC | $31.47 | 2025 | |
| Dexcom, INC. | $31.44 | 2024-2025 | Dexcom G6 Transmitter |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $25.95 | 2020 | |
| Shield Therapeutics INC | $24.96 | 2024 | |
| Ucb, INC. | $24.63 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.58 | 2019-2020 | |
| Eisai INC. | $24.52 | 2023 | |
| Amgen INC. | $21.98 | 2024 | Repatha |
| Phathom Pharmaceuticals, INC. | $21.67 | 2025 | Voquezna |
| Lilly USA, LLC | $21.57 | 2023 | Amyvid |
| Abbvie INC. | $19.33 | 2025 | |
| Gilead Sciences, INC. | $19.04 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.02 | 2023 | Xifaxan, Trulance |
| Avanir Pharmaceuticals, INC. | $16.78 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.53 | 2023 | |
| Idorsia Pharmaceuticals US INC | $16.19 | 2023 | Quviviq |
| Paratek Pharmaceuticals, INC. | $15.53 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.37 | 2025 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $11.18 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maimoona Nizami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.